RSV Cases Are Rising in Kids and Babies. What Parents Should Know
On top of continued concerns about COVID-19 and the anticipated wave of flu cases this fall and winter, health experts are also confronting another infectious disease: Respiratory syncytial virus (RSV).
RSV typically strikes during the colder months, when people gather indoors and are more likely to spread disease through close contact and respiratory droplets. It’s particularly common among infants and young children, as well as the elderly, who are more vulnerable to infections because of their less developed or weakened immune systems.
After years of having no vaccines against the virus, scientists are moving quic...
Source: TIME: Health - November 1, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Public Health Source Type: news
Letter to the Editor: Bronchiolitis Guidelines, tPA Supported by Science
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - November 1, 2022 Category: Emergency Medicine Tags: Letter to the Editor Source Type: news
Preparing kids for a flu shot: Tips to help parents
Cold and flu season is approaching, and that means it's time for flu shots. The Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend flu shots for children 6 months and older to protect themselves and their friends and family from the flu. There are two options available — a shot or nasal mist — that your family can use to prevent complications from the flu, such as pneumonia and bronchiolitis. The… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 31, 2022 Category: Databases & Libraries Source Type: news
RSV in children: Parents warned over signs of virus
Respiratory syncytial virus is the most common cause of bronchiolitis in children aged under two. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 30, 2022 Category: Consumer Health News Source Type: news
M2E Too!: The Nihilistic AAP Bronchiolitis Guidelines
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - September 1, 2022 Category: Emergency Medicine Tags: M2E Too! Source Type: news
What Are Causes of Childhood Interstital Lung Disease?
Discussion
Interstitial lung disease in children (chILD) is less understood than adult interstitial lung disease (ILD) and is rare. Prevalence is ~ 0.13 to 16.2 per 100,000 children under age 17 years. chILD is an general term for respiratory disorders that are heterogeneous, chronic and impair lung function. While some define diffuse parenchymal lung disease (DPLD) separately, the term ILD usually encompases DPLD. chILD has variable definitions and is “usually diagnosed if three of the following features are present:
1) respiratory symptoms (cough, rapid and/or difficult breathing, and exercise intolerance),
2) res...
Source: PediatricEducation.org - August 1, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Azithromycin Therapy Does Not Reduce Recurrent Wheeze After RSV
MONDAY, March 14, 2022 -- Azithromycin therapy during acute severe respiratory syncytial virus (RSV) bronchiolitis does not reduce recurrent wheeze over two to four years, according to a study published online Feb. 27 in NEJM Evidence.
Avraham... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 14, 2022 Category: Pharmaceuticals Source Type: news
Azithromycin Doesn't Prevent Wheezing After Acute Infant RSV Azithromycin Doesn't Prevent Wheezing After Acute Infant RSV
Azithromycin administered for severe early-life respiratory syncytial virus bronchiolitis did not prevent recurrent wheezing in affected children over the next 2-4 years.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2022 Category: Consumer Health News Tags: Pediatrics News Source Type: news
Infant Bronchiolitis Subtype May Predict Asthma Risk Infant Bronchiolitis Subtype May Predict Asthma Risk
Researchers identified four bronchiolitis subtypes that may determine infants at risk of asthma later in childhood.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 4, 2022 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news
Ethnic Disparities Seen in Enrollment for a Clinical Trial
WEDNESDSAY, Jan. 19, 2022 -- In the Bronchiolitis Follow-up Intervention Trial (BeneFIT) setting, physicians more often determined that Hispanic patients were not appropriate for as-needed follow-up and excluded them from the trial, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 19, 2022 Category: Pharmaceuticals Source Type: news
Ask the Mayo Mom: RSV and bronchiolitis - what to expect this season
Respiratory syncytial virus (RSV) causes infections of the lungs and respiratory tract. It's so common that most children have been infected with the virus by age 2. RSV can cause severe infection in some people, especially premature infants, older adults, people with heart and lung disease, or anyone with a weak immune system. In severe cases, RSV infection can spread to the lower respiratory tract, causing pneumonia or bronchiolitis — inflammation of the small airway passages entering… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 17, 2021 Category: Databases & Libraries Source Type: news
Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection against Lower Respiratory Infections in Older Adults
RARITAN, N.J., October 2, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV, demonstrating vaccine efficacy of 80 percent (CI, 52.2-92.9%) in adults aged 65 and older. The study results were presented as a late-breaking abstract at the virtual IDWeek 2021 conference on October 2.“The findings from our CYPRESS study are very encouraging as we seek to deliver a long-awaited preventive vaccine to stave off the severe ...
Source: Johnson and Johnson - October 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
RARITAN, N.J., September 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the initiation of its Phase 3 EVERGREEN study. The study will evaluate the efficacy, safety and immunogenicity of Janssen’s investigational adult vaccine against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), when compared with placebo in approximately 23,000 adults aged 60 years and older throughout North America and a selection of countries across Europe, Asia and the Southern Hemisphere.The EVERGREEN study was initiated based on positive results from the Phase 2b CYPR...
Source: Johnson and Johnson - September 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Bronchiolitis in children: diagnosis and management NICE guideline [NG9], (updated 9th August 2021)
This guideline covers diagnosing and managing bronchiolitis in babies and children. It aims to help healthcare professionals diagnose bronchiolitis and identify if babies and children should be cared for at home or in hospital. It describes treatments and interventions that can be used to help with the symptoms of bronchiolitis. In August 2021, the recommendations on oxygen saturation thresholds for referral to hospital, admission, management and timing of discharge were updated. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 13, 2021 Category: Consumer Health News Source Type: news
Data for Roche ’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
Basel, 29 July 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH Part 2, a pivotal global study evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies aged 1-7 months old with symptomatic Type 1 spinal muscular atr ophy (SMA). The study met its primary endpoint with 29% of infants (12/41) sitting without support for at least five seconds* by month 12, a milestone not seen in the natural course of the disease. Safety for Evrysdi in the FIREFISH Part 2 study was consistent with its known safety profile.“Without treatme...
Source: Roche Investor Update - July 29, 2021 Category: Pharmaceuticals Source Type: news
